Vivek C. Abraham

Vivek C. Abraham

Auto-generated profile, based on publicly available information

Vivek C. Abraham

AbbVie, Renal Discovery, Chicago, Illinois

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 1999 in Biophysical Journal
Verified
Journal Article
Closed access
VAVivek C. Abraham
Vivek C. Abraham
VKVijaykumar Krishnamurthi
Vijaykumar Krishnamurthi
DTD. Lansing Taylor
D. Lansing Taylor
FLFrederick Lanni
Frederick Lanni

1 January 2004 in Trends in Biotechnology
Verified
Journal Article
Closed access
VAV Abraham
V Abraham

1 July 2008 in SLAS Discovery
Verified
Journal Article
Open access
VAVivek C. Abraham
Vivek C. Abraham
DTDanli L. Towne
Danli L. Towne
JWJeffrey F. Waring
Jeffrey F. Waring
UWUsha Warrior
Usha Warrior
DBDavid J. Burns
David J. Burns
Prioritization of compounds based on human hepatotoxicity potential is currently a key unmet need in drug discovery, as it can become a major problem for several lead compounds in later stages of the drug discovery pipeline. The authors report the validation and implementation of a high-content multiparametric cytotoxicity assay based on simultaneous measurement of 8 key cell health indicators associated with nuclear morphology, plasma membrane integrity, mitochondrial function, and cell proliferation. Compounds are prioritized by (a) computing an in vitro safety margin using the minimum cytotoxic concentration (IC20) across all 8 indicators and cell-based efficacy data and (b) using the minimal cytotoxic concentration alone to take into account concentration of drug in tissues. Feasibility data using selected compounds, including quinolone antibiotics, thiazolidinediones, and statins, suggest the viability of this approach. To increase overall throughput of compound prioritization, the authors have identified the higher throughput, plate reader—based CyQUANT® assay that is similar to the high-content screening (HCS) assay in sensitivity of measuring inhibition of cell proliferation. It is expected that the phenotypic output from the multiparametric HCS assay in combination with other highly sensitive approaches, such as microarray-based expression analysis of toxic signatures, will contribute to a better understanding and predictivity of human hepatotoxicity potential. (Journal of Biomolecular Screening 2008: 527-537)

1 April 1993 in The Biological Bulletin
Verified
Journal Article
Open access
VAV. C. Abraham
V. C. Abraham
SGS. Gupta
S. Gupta
RFR. A. Fluck
R. A. Fluck
Using time-lapse video microscopy, we found that ooplasmic inclusions in the fertilized medaka egg displayed two types of movement during ooplasmic segregation. The first manifested itself as the movement of many inclusions (diameter = 1.5-11 μm) toward the animal pole at about 2.2 μm min-1; this type of movement appeared to be streaming. The second type of movement was faster (about 44 μm min-1) and saltatory; inclusions displaying this type of movement were smaller (diameter ≤1.0 μm) and moved toward the vegetal pole. The movement of oil droplets toward the vegetal pole of the egg may represent a third type of motion. All these movements began only after a strong contraction of the ooplasm toward the animal pole, which at 25°C began 10-12 min after fertilization and <3 min after formation of the second polar body. In eggs treated with microtubule poisons--colchicine, colcemid, or nocodazole--oil droplets did not move toward the vegetal pole, saltatory motion toward the vegetal pole was absent, and the growth of the blastodisc was slowed. Eggs treated with β-lumicolchicine, an inactive derivative of colchicine, showed normal movements. Colchicine, while not inhibiting formation of the second polar body, did inhibit pronuclear migration. These results suggest that microtubules are involved in the movement of some ooplasmic inclusions, including oil droplets, toward the vegetal pole; the movement of ooplasmic inclusions toward the animal pole; and pronuclear migration.

1 September 2012 in SLAS Discovery
Verified
Journal Article
Open access
PDF file
DTDanli L. Towne
Danli L. Towne
ENEmily E. Nicholl
Emily E. Nicholl
KCKenneth M. Comess
Kenneth M. Comess
SGScott C. Galasinski
Scott C. Galasinski
PHPhilip J. Hajduk
Philip J. Hajduk
VAVivek C. Abraham
Vivek C. Abraham
Efficient elucidation of the biological mechanism of action of novel compounds remains a major bottleneck in the drug discovery process. To address this need in the area of oncology, we report the development of a multiparametric high-content screening assay panel at the level of single cells to dramatically accelerate understanding the mechanism of action of cell growth–inhibiting compounds on a large scale. Our approach is based on measuring 10 established end points associated with mitochondrial apoptosis, cell cycle disruption, DNA damage, and cellular morphological changes in the same experiment, across three multiparametric assays. The data from all of the measurements taken together are expected to help increase our current understanding of target protein functions, constrain the list of possible targets for compounds identified using phenotypic screens, and identify off-target effects. We have also developed novel data visualization and phenotypic classification approaches for detailed interpretation of individual compound effects and navigation of large collections of multiparametric cellular responses. We expect this general approach to be valuable for drug discovery across multiple therapeutic areas.

1 November 1999 in Zygote
Verified
Journal Article
Closed access
PDF file
RFRichard Fluck
Richard Fluck
VAVivek Abraham
Vivek Abraham
AMAndrew Miller
Andrew Miller
AGAntony Galione
Antony Galione
Medaka (Oryzias latipes) eggs microinjected with the Ca2+-mobilising messenger cyclic adenosine diphosphate ribose (cADPR) underwent a wave of exocytosis of cortical alveoli and were thus activated. The number of eggs activated was sharply dependent on the concentration of cADPR in the pipette, the threshold concentration was approximately 60 nM. After injection, a pronounced latency preceded the onset of cortical alveoli exocytosis; this latency was independent of the concentration of cADPR but decreased markedly with increasing temperature. Heat-treated cADPR, which yields the inert non-cyclised product ADP-ribose, was ineffective in activating eggs. When cADPR was injected into aequorin-loaded eggs, a wave of luminescence arose at the site of cADPR injection and then swept out across the egg with a mean velocity of approximately 13 μm/s; the velocity was independent of the concentration of injected cADPR. In such a large cell (diameter of around 1 mm), this is considerably faster than that possible by simple diffusion of cADPR, which unambiguously demonstrates that cADPR must activate a regenerative process. cADPR has been demonstrated to modulate Ca2+-induced Ca2+ release (CICR) via ryanodine receptors (RyRs) in many cell types, and consistent with this was the finding that microinjection of the pharmacological RyR modulator, ryanodine, also activated medaka eggs. These results suggest that a cADPR-sensitive Ca2+ release mechanism is present in the medaka egg, that cADPR is the most potent activator of medaka eggs described to date, and that it activates eggs by triggering a wave of CICR from internal stores that in turn stimulates a wave of exocytosis.